Post-Makary, New Rare Disease Framework Faces Fresh Uncertainty

Why It Matters

Unclear regulatory direction threatens investment and timelines for ultra‑rare biotech programs, potentially slowing life‑saving treatments to patients with few alternatives.

Key Takeaways

• FDA leadership turnover puts plausible mechanism pathway future in doubt
• Workshop clarified framework applies to genome editing and RNA therapies
• External control guidance remains inconsistent, confusing rare‑disease sponsors
• Industry wants broader use beyond N‑of‑1 to sustain business
• Manufacturing CMC standards challenge small biotech feasibility

Pulse Analysis

The plausible mechanism pathway emerged in late 2025 as the FDA’s answer to a growing pipeline of bespoke gene‑editing and antisense therapies targeting ultra‑rare conditions. Championed by Commissioner Marty Makary and CBER director Vinay Prasad, the initiative promised a flexible evidentiary standard—seven pillars that focus on disease severity, mechanistic plausibility, and real‑world data—without creating a brand‑new regulatory track. However, the sudden exit of both architects in early 2026 has left sponsors scrambling for clarity, prompting a May workshop that sought to solidify the framework’s intent while acknowledging the leadership vacuum.

At the workshop, FDA officials emphasized that the pathway remains an application of existing approval routes, not a separate process, and highlighted its relevance to genome‑editing, RNA‑based, and antisense modalities. Yet participants noted persistent ambiguity around external controls, with recent rejections of rare‑disease submissions that relied on historical or real‑world comparators fueling industry frustration. Companies like Saol Therapeutics argue that overly prescriptive criteria could exclude promising multi‑variant diseases such as pyruvate dehydrogenase complex deficiency, which affects fewer than 1,000 U.S. patients. The FDA’s draft guidance hints at broader applicability, but the line between N‑of‑1 therapies and small‑population drugs remains undefined.

The stakes extend beyond scientific feasibility. Venture capitalists and biotech founders view the pathway as a potential bridge between high‑cost, low‑volume therapies and sustainable business models. Yet manufacturing hurdles—especially the requirement for CMC maturity near BLA standards—pose significant cost barriers for early‑stage firms. Without clearer regulatory signals and a more pragmatic approach to external controls, the plausible mechanism framework risks becoming a niche tool rather than a catalyst for a new wave of rare‑disease innovations, leaving patients and investors alike in limbo.